Peptide legal risks for physicians remain after FDA compounding pause

Physicians who prescribe unapproved peptides still face peptide legal risks at the state and federal level, two health care attorneys wrote on November 6. Their warning follows a federal policy that paused FDA enforcement against pharmacies compounding six such peptides. Gary W. Herschman and Mark Yacura of the law firm Baker Donelson set out the risks in an expert submission to Healio's Orthopedics Today. They list license discipline, criminal charges, fraud suits and malpractice claims. The attorneys wrote that the FDA pause does not stop state regulators from acting on their own.

What the attorneys warn

The piece draws a line between approved and unapproved products. Prescribing semaglutide, sold by Novo Nordisk as Ozempic and Wegovy, or tirzepatide, sold by Eli Lilly as Mounjaro and Zepbound, for approved uses raises few regulatory problems, the authors wrote. Their concern is the wider group of unapproved peptides that compounding pharmacies now make and that are prescribed and promoted for many uses. Doctors who prescribe, source, promote or give peptides that lack FDA approval, or that are missing from the FDA bulk substances lists, face regulatory, civil and even criminal exposure, according to the attorneys. These peptide legal risks start with the license. State medical boards can discipline, fine or revoke the license of a doctor whose prescribing or compounding breaks FDA rules, they wrote.

Healio labels the article an expert submission, and a Healio editor fact checked it. It is a legal commentary, not a court ruling or agency guidance. Herschman disclosed that he has worked as a health care transaction attorney for more than 30 years and serves as co-chair of the health care transactions group at Baker Donelson. Yacura reported no relevant financial disclosures. The piece does not name any physician who has been charged, give a count of cases or cite court filings. It also does not name the six peptides covered by the federal pause. Earlier Peptide Zone reporting found that the interim policy covers BPC 157, epitalon, KPV, MOTS c, Semax and TB 500. None of the six is FDA approved.

FDA enforcement discretion has limits

The attorneys trace the federal timeline. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six peptides to the Section 503A bulk substances list. A listing would let compounding pharmacies make them under strict conditions without fear of current FDA enforcement. The committee only advises, the authors noted, so the agency can accept the vote, reject it or take a long time to act. On October 14, the FDA sent the White House an interim policy saying it would use enforcement discretion and pause action against pharmacies that source the six bulk peptides for compounding. The White House Office of Management and Budget affirmed the proposal on October 27, and the Federal Register published the formal policy on October 30, according to the article.

The FDA pause lasts until a final rule on the six peptides is complete or until the agency sees a safety problem with any of them, the attorneys wrote.

The FDA pause lasts until a final rule on the six peptides is complete or until the agency sees a safety problem with any of them, the attorneys wrote. FDA enforcement discretion here is therefore interim, not permanent. It also leaves state power in place. Many state boards of pharmacy and state attorneys general can act on their own against unapproved compounded peptides under state law, whatever a federal committee recommends or the FDA decides, according to the piece. The article does not say which states have used that power. Peptide Zone did not independently review the Federal Register notice for this story. Public comments on the policy close November 13, according to earlier Peptide Zone reporting on the policy's evidence base.

Research use only peptides and criminal exposure

The attorneys describe federal criminal exposure for some doctors. Federal prosecutors have presented evidence to grand juries that indicted licensed physicians who ordered unapproved peptides from overseas or from unverified third party intermediaries and then dispensed them to patients, they wrote. Sourcing or selling unapproved, misbranded or research use only peptides can lead to federal criminal action against a doctor who prescribes or dispenses them, or who promotes them for clinically unproven uses, according to the piece. The article gives no names, dates, courts or case numbers for these indictments. The scale of federal enforcement therefore cannot be judged from the commentary alone. Readers should treat the claim as the authors' account of current practice rather than as a documented tally of prosecutions.

Product quality is where much of the liability lands, the authors argue. A doctor who buys peptides from unverified online vendors or research only suppliers, rather than from licensed and compliant compounding pharmacies, takes on legal responsibility for any contamination, mislabeling or purity failure, they wrote. That point matters because peptide legal risks in this area follow the product as well as the prescription. Quality failures in the unapproved market have already reached patients. Peptide Zone has reported a case of acute liver failure in an Australian woman who injected a vial labelled as an experimental drug, although no physician was linked to that case. The attorneys name licensed and compliant compounding pharmacies as the lawful channel for compounded peptides.

Informed consent and malpractice claims

Marketing creates a separate exposure. A doctor who claims that an unapproved peptide can prevent or treat a disease or medical condition, without competent and reliable scientific evidence, may face civil fraud, deceptive trade practice or consumer protection suits under federal and state law, the attorneys wrote. Malpractice is the next layer. Giving or recommending experimental or off label peptides that lack rigorous placebo controlled human trials exposes doctors to lawsuits if patients suffer serious adverse reactions, unexpected side effects or death, according to the piece. That evidence gap is documented. A Men's Health review covered by Peptide Zone found that most support for the six peptides in the federal policy comes from animal or cell studies, not from controlled trials in people.

The attorneys say doctors have a legal duty to tell patients when a therapy is experimental. That includes saying the peptide is not FDA approved, that it lacks long term human safety data and what side effects may occur. Weak records or a poor consent process expose a doctor to legal claims if serious or life threatening adverse events follow, they wrote. Informed consent is therefore both a patient safety step and a legal record. What happens to these peptide legal risks next rests with regulators. The FDA has not completed the final rule that would decide whether the six peptides join the bulk list, and the article gives no timeline. Until then, the attorneys' reading is that the federal pause helps pharmacies but leaves a prescriber's state and civil exposure in place.

Conclusion

Peptide legal risks for physicians did not end with the federal compounding pause, according to two Baker Donelson attorneys writing in Healio. The FDA policy covers pharmacies compounding six peptides and lasts only until a final rule or a safety signal. State boards, prosecutors, plaintiffs and patients can still act. The commentary names no cases, so its claims about indictments cannot be checked from the text. The next marker is the November 13 comment deadline, followed by any final FDA rule on the six peptides.